Assessment of drug-induced mitochondrial dysfunctions is important in drug development as well as in the understanding of molecular mechanism of therapeutic or adverse effects of drugs. The aim of this study was to investigate the effects of three typical antipsychotics (APs) and seven atypical APs on mitochondrial bioenergetics. The effects of selected APs on citrate synthase, electron transport chain complexes (ETC), and mitochondrial complex I- or complex II-linked respiratory rate were measured using mitochondria isolated from pig brain. Complex I activity was decreased by chlorpromazine, haloperidol, zotepine, aripiprazole, quetiapine, risperidone, and clozapine. Complex II + III was significantly inhibited by zotepine, aripiprazole, quetiapine, and risperidone. Complex IV was inhibited by zotepine, chlorpromazine, and levomepromazine. Mitochondrial respiratory rate was significantly inhibited by all tested APs, except for olanzapine. Typical APs did not exhibit greater efficacy in altering mitochondrial function compared to atypical APs except for complex I inhibition by chlorpromazine and haloperidol. A comparison of the effects of APs on individual respiratory complexes and on the overall mitochondrial respiration has shown that mitochondrial functions may not fully reflect the disruption of complexes of ETC, which indicates AP-induced modulation of other mitochondrial proteins. Due to the complicated processes associated with mitochondrial activity, it is necessary to measure not only the effect of the drug on individual mitochondrial enzymes but also the respiration rate of the mitochondria or a similar complex process. The experimental approach used in the study can be applied to mitochondrial toxicity testing of newly developed drugs.

Department of Psychiatry 1st Faculty of Medicine Charles University and General University Hospital Prague Ke Karlovu 11 120 00 Prague 2 Czech Republic

Institute of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Albertov 4 128 00 Prague 2 Czech Republic

Zobrazit více v PubMed

Neuropharmacology. 1999 Apr;38(4):567-77 PubMed

Schizophr Bull. 1999;25(4):731-40 PubMed

Structure. 2000 Jun 15;8(6):669-84 PubMed

Am J Psychiatry. 2001 Mar;158(3):360-9 PubMed

Schizophr Res. 2001 Mar 1;48(1):125-36 PubMed

J Clin Psychiatry. 2001;62 Suppl 21:15-8 PubMed

Am J Psychiatry. 2001 Nov;158(11):1774-82 PubMed

Arzneimittelforschung. 2001 Oct;51(10):785-92 PubMed

Can J Psychiatry. 2002 Feb;47(1):27-38 PubMed

Drugs. 2002;62(11):1649-71 PubMed

Acta Psychiatr Scand. 2003 Feb;107(2):85-95 PubMed

CNS Drugs. 2003;17(6):423-30 PubMed

Biol Psychiatry. 2003 Nov 15;54(10):1049-59 PubMed

Arch Pharm Res. 2003 Nov;26(11):951-9 PubMed

J Biol Chem. 1951 Nov;193(1):265-75 PubMed

Prim Care Companion J Clin Psychiatry. 2003 Oct;5(5):205-215 PubMed

Br J Psychiatry. 2005 Jan;186:7-10 PubMed

Cell. 2005 Jul 1;121(7):1043-57 PubMed

N Engl J Med. 2005 Sep 22;353(12):1209-23 PubMed

CNS Spectr. 2005 Oct;10(10):suppl14 1-15 PubMed

Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 PubMed

J Clin Psychopharmacol. 2007 Jun;27(3):284-8 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2007 Oct;376(1-2):127-33 PubMed

Mol Psychiatry. 2008 Jan;13(1):27-35 PubMed

Results Probl Cell Differ. 2008;45:253-78 PubMed

Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):777-82 PubMed

Lancet. 2009 Jan 3;373(9657):31-41 PubMed

Neurochem Int. 2010 Feb;56(3):394-403 PubMed

Neuro Endocrinol Lett. 2010;31(3):336-42 PubMed

Neurosci Lett. 2011 Jan 10;487(3):278-81 PubMed

Neuro Endocrinol Lett. 2010;31(5):645-56 PubMed

Nature. 2011 Aug 07;476(7361):414-20 PubMed

Methods Mol Biol. 2012;810:25-58 PubMed

J Neurochem. 2012 Feb;120(3):371-84 PubMed

J Neural Transm (Vienna). 2012 Nov;119(11):1327-42 PubMed

Toxicol Lett. 2012 Sep 18;213(3):345-52 PubMed

Biochim Biophys Acta. 2013 May;1827(5):648-57 PubMed

Lancet. 2013 Sep 14;382(9896):951-62 PubMed

Trends Neurosci. 1989 Mar;12(3):94-101 PubMed

PLoS One. 2014 Jun 18;9(6):e100054 PubMed

Autophagy. 2014;10(12):2362-78 PubMed

Xenobiotica. 2016;46(4):369-78 PubMed

Curr Alzheimer Res. 2016;13(8):930-41 PubMed

Folia Biol (Praha). 2016;62(1):15-25 PubMed

Folia Biol (Praha). 2016;62(2):53-66 PubMed

Nature. 2016 Oct 20;538(7625):406-410 PubMed

Schizophr Res. 2017 Sep;187:17-25 PubMed

Toxicol Lett. 2017 Apr 15;272:94-100 PubMed

Oncotarget. 2017 Jun 6;8(23):37568-37583 PubMed

Pharmacopsychiatry. 2018 Jan;51(1-02):9-62 PubMed

Nat Struct Mol Biol. 2017 Oct 5;24(10):800-808 PubMed

Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):383-390 PubMed

Eur Neuropsychopharmacol. 2018 Mar;28(3):369-380 PubMed

Subcell Biochem. 2018;87:167-227 PubMed

Front Endocrinol (Lausanne). 2018 Apr 23;9:144 PubMed

Trends Cell Biol. 2018 Oct;28(10):835-867 PubMed

Early Interv Psychiatry. 2019 Oct;13(5):1032-1049 PubMed

Arzneimittelforschung. 1979;29(10):1595-600 PubMed

Nature. 1974 Jun 14;249(458):664-6 PubMed

Br J Pharmacol. 1983 Apr;78(4):671-9 PubMed

Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S46-52 PubMed

Science. 1995 Aug 25;269(5227):1069-74 PubMed

Clin Chim Acta. 1994 Jul;228(1):35-51 PubMed

Ann Neurol. 1993 May;33(5):512-7 PubMed

Am J Psychiatry. 1995 Dec;152(12):1730-6 PubMed

Methods Enzymol. 1996;264:484-509 PubMed

J Pharmacol Exp Ther. 1997 Jan;280(1):261-7 PubMed

Mol Cell Biochem. 1997 Sep;174(1-2):255-9 PubMed

Biochim Biophys Acta. 1998 May 6;1364(2):261-70 PubMed

Science. 1998 Jul 3;281(5373):64-71 PubMed

In vitro effects of antidepressants and mood-stabilizing drugs on cell energy metabolism